Aclaris Therapeutics Inc
Company Profile
Business description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Contact
701 Lee Road
Suite 103
WaynePA19087
USAT: +1 484 324-7933
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
73
Stocks News & Analysis
stocks
Weight loss drugs not an existential threat to undervalued ASX share
stocks
Tesla: valuation is key consideration in merger talks with SpaceX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,968.80 | 42.20 | 0.47% |
| CAC 40 | 7,901.13 | 53.81 | 0.69% |
| DAX 40 | 25,609.72 | 198.88 | 0.78% |
| Dow JONES (US) | 52,393.48 | 31.90 | 0.06% |
| FTSE 100 | 10,688.88 | 78.45 | -0.73% |
| HKSE | 23,041.32 | 170.49 | -0.73% |
| NASDAQ | 26,515.94 | 346.56 | 1.32% |
| Nikkei 225 | 63,268.37 | 1,078.72 | 1.73% |
| NZX 50 Index | 13,680.27 | 53.66 | -0.39% |
| S&P 500 | 7,728.91 | 52.14 | 0.68% |
| S&P/ASX 200 | 8,850.10 | 40.20 | 0.46% |
| SSE Composite Index | 3,648.30 | 49.22 | -1.33% |